Cell News and Research

RSS

Pancreatic trigs trigger diabetes

Researchers have found that pancreatic triglycerides provide a novel biomarker for pancreatic β-cell dysfunction that can be used to identify individuals at risk for Type 2 diabetes, particularly among people of Hispanic origin.

14 Sep 2012

Objective response rate promising after crizotinib for NSCLC

More than half of the latest evaluated participants from the ongoing phase II PROFILE 1005 trial of crizotinib against ALK-positive advanced non-small-cell lung cancer, achieved an objective tumor response, report researchers.

14 Sep 2012

EMAS clinical guide on low-dose vaginal estrogens for postmenopausal vaginal atrophy

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today the publication of a position statement by the European Menopause and Andropause Society (EMAS) in the journal Maturitas.

14 Sep 2012

Genomes of lung cancer smokers have more mutations

Lung cancer patients with a history of smoking have 10 times more genetic mutations in their tumors than those with the disease who have never smoked, according to a new study from Washington University School of Medicine in St. Louis.

14 Sep 2012

Humans could learn from how plants handle stress

Humans could learn from how plants handle stress. Federica Brandizzi, Michigan State University plant biologist, is using a grant from the National Institutes of Health to study how plants overcome stress as they grow. These pathways used to overcome stress are a key to growth. Without them plants, and animals, would die.

14 Sep 2012

Dual role of ghrelin in anxiety behavior is context-dependent

Ghrelin is a hormone released by the lining of the stomach that promotes feeding behavior. Decreasing ghrelin levels could potentially help combat obesity -- in fact, a vaccine that lowers ghrelin levels in order to reduce appetite is being studied as a treatment for obesity.

14 Sep 2012

Researchers regenerate axons at spinal cord injury site

In a study at the University of California, San Diego and VA San Diego Healthcare, researchers were able to regenerate "an astonishing degree" of axonal growth at the site of severe spinal cord injury in rats.

14 Sep 2012

Researchers clone T-cell receptor that binds to antigens associated with prostate and breast cancer

Researchers at Uppsala University have cloned a T-cell receptor that binds to an antigen associated with prostate cancer and breast cancer. T cells that have been genetically equipped with this T-cell receptor have the ability to specifically kill prostate and breast cancer cells.

14 Sep 2012

UMass Amherst develops 'chemical nose' array to detect metastatic cancers

In the fight against cancer, knowing the enemy's exact identity is crucial for diagnosis and treatment, especially in metastatic cancers, those that spread between organs and tissues. Now chemists led by Vincent Rotello at the University of Massachusetts Amherst have developed a rapid, sensitive way to detect microscopic levels of many different metastatic cell types in living tissue. Findings appear in the current issue of the journal ACS Nano.

14 Sep 2012

HIF-1a protein of hypoxia creates CD24 overexpression in many tumors

It seems as if a tumor deprived of oxygen would shrink. However, numerous studies have shown that tumor hypoxia, in which portions of the tumor have significantly low oxygen concentrations, is in fact linked with more aggressive tumor behavior and poorer prognosis.

14 Sep 2012

Emmaus Medical to complete target enrollment in L-Glutamine Phase III trial for sickle cell disease

In conjunction with Sickle Cell Awareness Month, Emmaus Medical, Inc., a specialty pharmaceutical and regenerative medicine technology company, announced that its U.S. Phase III clinical trial to study L-Glutamine as a treatment for sickle cell disease is nearing target enrollment completion, with investigation now underway at more than 30 clinical study sites throughout the U.S.

14 Sep 2012

Neuralstem prices registered direct offering of 7,000,000 shares of common stock

Neuralstem, Inc. today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share.

14 Sep 2012

Scientists describe how DNA origami can enhance effect of cytostatics in cancer treatment

Scientists at Karolinska Institutet in Sweden describe in a new study how so-called DNA origami can enhance the effect of certain cytostatics used in the treatment of cancer. With the aid of modern nanotechnology, scientists can target drugs direct to the tumour while leaving surrounding healthy tissue untouched.

14 Sep 2012